Targeted next-generation sequencing extends the mutational spectrums for \textit{OPA1} mutations in Chinese families with optic atrophy

Yuwei Wang,\textsuperscript{1} Min Xu,\textsuperscript{2,3} Xiaoxing Liu,\textsuperscript{4} Yongheng Huang,\textsuperscript{1} Yao Zhou,\textsuperscript{1} Qinghuai Liu,\textsuperscript{3} Xue Chen,\textsuperscript{3} Chen Zhao,\textsuperscript{2,5} Min Wang\textsuperscript{6}

(The first three authors contributed equally to this article.)

\textsuperscript{1}Department of Ophthalmology and Vision Science, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China; \textsuperscript{2}Department of Ophthalmology, Northern Jiangsu People’s Hospital, Yangzhou, China; \textsuperscript{3}Department of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; \textsuperscript{4}Department of Ophthalmology, Xuzhou Central Hospital, Xuzhou, China; \textsuperscript{5}Key NHC Key Laboratory of Myopia (Fudan University) and Laboratory of Myopia, Chinese Academy of Medical Sciences

\textbf{Purpose:} We aim to reveal the disease-causing mutations in 15 Chinese families with optic atrophy (OA).

\textbf{Methods:} In total, 15 families with OA were recruited in the present study. Medical histories were carefully reviewed and comprehensive ophthalmic examinations were received by all recruited patients. Targeted next-generation sequencing (NGS) was selectively performed on all probands for mutation detection. Intrafamilial cosegregation and in-silico analyses were subsequently applied to predict the potential pathogenic effects of identified mutations.

\textbf{Results:} All included patients presented bilateral vision loss. Their fundus photographs showed temporal or total pallor of the optic discs. Fourteen mutations in the optic atrophy 1 (\textit{OPA1}) gene were revealed as disease-causing mutations for the 15 families, including eight novel (c.968A>G, c.193C>G, c.1071dupT, c.987_988del, c.2012+2T>G, c.1036–1G>C, c.2126A>G, and c.1036_1038del) and six recurrent (c.1499G>A, c.1800C>A, c.1034G>A, c.2873_2876del, c.112C>T, and c.804_805del) mutations.

\textbf{Conclusions:} In conclusion, our study expands the mutational spectrum for the \textit{OPA1} gene and implies targeted NGS as an effective approach for the genetic diagnosis of OA, which might help to improve the clinical diagnosis for patients with OA.

Inherited optic atrophy (OA) is characterized by the degeneration of retinal ganglion cells (RGCs) and other neuronal populations, which results in thinning of the retinal nerve fiber layer (RNFL) [1]. Typical clinical features of OA include progressive loss of bilateral vision (usually occurs within the first decade), central or paracentral scotomas, tritanopia, and pallor of the optic discs [1-3]. Familial history, temporal or diffuse pallor of the optic discs disclosed by eye fundus, and a reduced amplitude of the waveform detected by visually evoked potentials (VEP) may contribute to the clinical diagnosis of OA [2]. According to the inheritance pattern, OA can be categorized into autosomal dominant optic atrophy (ADOA) and mitochondrial inherited Leber hereditary optic neuropathy (LHON). ADOA, showing a worldwide prevalence of 1:50,000, is the most common form of inherited optic neuropathy [3].

ADOA shows genetic heterogeneity [2,4]. To date, two genes, optic atrophy 1 (\textit{OPA1}, OMIM\textsubscript{605290}) and \textit{OPA3} (OMIM\textsubscript{606580}), and three loci, \textit{OPA4} (OMIM\textsubscript{605293}), \textit{OPA5} (OMIM\textsubscript{610708}), and \textit{OPA8} (OMIM\textsubscript{616648}), are reported to be correlated with ADOA. Among all, \textit{OPA1} is the most common causative gene for ADOA [5]. \textit{OPA1} consists of 31 coding exons, and it encodes dynamin-like guanosine triphosphates (GTPase) localized to the mitochondria. Protein encoded by \textit{OPA1} targets the external face of the mitochondrial inner membrane, controls the structural integrity of mitochondrial cristae, and keeps their junctions tight during apoptosis [6]. To date, over 400 variants in \textit{OPA1} have been identified (mitodyn). About 20% of all identified variants associate with the “ADOA plus” syndrome [7,8]. Patients with “ADOA plus” syndrome present OA in childhood, followed by the subsequent onset of chronic progressive external ophthalmoplegia (PEO), ptosis, sensorineural deafness, peripheral neuropathy, and myopathy in adult life [9]. Most reported \textit{OPA1} mutations are missense mutations located in the GTPase domain and dynamin central region, which interrupt the protein function [2,10].
Next-generation sequencing (NGS), an approach that enables sequencing of a panel of candidate genes, has been revealed as an efficient tool for the molecular diagnosis of inherited retinal dystrophies (IRDs) [2,10]. Because no effective clinical therapy has been developed for OA, NGS-based molecular diagnosis will not only help to improve its clinical diagnosis, but is also essential for its prenatal diagnosis. Herein, by means of a targeted NGS approach, we reveal novel $\text{OPA1}$ mutations in 15 Chinese families with OA.

**METHODS**

**Participants and clinical investigations:** Our study complied with the Declaration of Helsinki, and it was approved and prospectively reviewed by the ethics committee of the First Affiliated Hospital of Nanjing Medical University (2017-SRFA-034). Written informed consent was obtained from all participants or their legal guardians before enrollment.

All participants underwent routine ophthalmic examinations, including best-corrected visual acuity (BCVA), funduscopy, slit-lamp examination, and fundus photography. The VEP test was selectively performed on patients OA02-II:1, OA08-II:1, and OA12-II:1. Another 150 unrelated Chinese controls were also included, each of whom received basic ophthalmic examinations to exclude major ocular problems. Peripheral blood samples from all participants were collected in EDTA tubes. DNA extraction from leukocytes was performed using a RelaxGene Blood DNA System (Qiagen, Valencia, CA) per the manufacturer’s protocols.

**Targeted gene capture. NGS, bioinformatics analyses, and Sanger sequencing:** Targeted sequence capture microarrays that could capture the coding and exon-intronic boundary regions of all known retinal disease genes were used in this study. Details of the targeted genes of the commercial array have been previously described [11-13]. Sequence capture, enrichment, elution, and NGS were conducted in cooperation.
with BGI-Shenzhen or MyGenostics-Beijing, as previously stated [14,15].

All detected variants were further filtered against the following six single nucleotide polymorphism (SNP) databases, including the dbSNP144, HapMap project, 1000 Genome Project, YH database, Exon Variant Server, and ExAC databases. Variants with a minor allele frequency value of over 0.001 were discarded. Sanger sequencing was subsequently performed for a mutation validation, intrafamilial genotype–phenotype cosegregation analysis, and prevalence test in 150 controls. Information of primers are listed in Appendix 1.

In-silico analyses: Evolutionary conservation of the mutated amino acids was analyzed through the alignment of OPA1 orthologous protein sequences from the following species: Homo sapiens (ENSP00000354681), Pan troglodytes (ENSPTRP00000027094), Bos taurus (ENSBTAP00000026013), Mus musculus (ENSRNOP0000002338), Gallus gallus (ENSGALP00000042204), Danio rerio (ENSDARP000000095031), Drosophila melanogaster (FBpp0086700), and Caenorhabditis elegans (D2013.5). Online predictive software, including SIFT [16], PolyPhen-2 [17], and PROVEN [18], was applied to evaluate the potential pathogenicity of identified mutations. The Splicing Regulation Online Graphical Engine (SROOGLE) online prediction software was used to determine whether splice site variations would alter the regular splicing sites.

RESULTS

Clinical manifestations: Family pedigrees are shown in Figure 1. All included patients presented typical OA symptoms, and their detailed clinical data are summarized in Table 1. Briefly, the onset ages varied from infant to 12 years old.

| Patient ID | Age (years) /Sex | Onset Age (years) | BCVA (logMAR) | Optic disc | VEP |
|------------|------------------|-------------------|---------------|------------|-----|
| OA01-II:3  | 60/F             | 3                 | 0.02          | 0.01       | Pale | NA  |
| OA01-III:1 | 38/M             | 8                 | 0.1           | 0.1        | Pale | NA  |
| OA01-IV:1  | 16/F             | 5                 | 0.05          | 0.05       | Pale | NA  |
| OA02-II:2  | 30/F Infant      |                   | 0.25          | 0.02       | Pale | NA  |
| OA03-II:1  | 8/M              | 3                 | 0.2           | 0.3        | Pale | NA  |
| OA04-II:2  | 16/M             | 6                 | 0.5           | 0.5        | Pale | NA  |
| OA05-II:1  | 10/M             | 6                 | 0.4           | 0.5        | Pale | NA  |
| OA06-I:1   | 42/M             | 12                | 0.5           | 0.4        | Pale | NA  |
| OA06-II:1  | 14/F             | 11                | 0.2           | 0.1        | Pale | NA  |
| OA07-II:2  | 9/M              | 4                 | 0.4           | 0.3        | Pale | NA  |
| OA08-I:1   | 32/M             | 8                 | 0.3           | 0.3        | Pale | Diminished |
| OA08-II:1  | 9/M              | 5                 | 0.5           | 0.4        | Pale | Diminished |
| OA09-II:1  | 8/M              | 5                 | 0.1           | 0.1        | Pale | NA  |
| OA10-II:2  | 9/M              | 7                 | 0.2           | 0.2        | Pale | NA  |
| OA11-II:1  | 43/F             | 12                | 0.1           | 0.1        | Pale | NA  |
| OA11-II:2  | 42/F             | 10                | 0.1           | 0.1        | Pale | NA  |
| OA12-I:1   | 30/M             | 8                 | 0.3           | 0.3        | Pale | Diminished |
| OA12-II:1  | 6/M              | 4                 | 0.3           | 0.3        | Pale | Diminished |
| OA13-I:2   | 31/F             | 6                 | 0.4           | 0.4        | Pale | NA  |
| OA13-II:1  | 7/M              | 4                 | 0.3           | 0.3        | Pale | NA  |
| OA14-I:2   | 28/F             | 6                 | 0.3           | 0.4        | Pale | NA  |
| OA14-II:1  | 6/M              | 3                 | 0.25          | 0.3        | Pale | NA  |
| OA15-II:1  | 14/M             | 6                 | 0.2           | 0.2        | Pale | NA  |

Abbreviations: OD: right eye; OS: left eye; F: female; M: male; BCVA: best corrected visual acuity; VEP: visual evoked potential; NA: not available.
Patient OA02-II:2 had vision defects since infancy, while patients from families OA06 and OA11 were completely unaffected until 10 to 12 years old. Most patients reported having bilateral visual impairments since their first decade of life, which was consistent with previous reports. The disease progression also varied. For example, patients OA06-I:1 and OA11-II:1 shared a similar age and onset age. However, the BCVAs for patient OA06-I:1 are 0.5 OD and 0.4 OS, while patient OA11-II:1 had much poorer visual conditions (0.1 OU). Rapid disease progression was also noticed in patient OA02-II:2. She also presented with asymmetric visual defects, with her BCVAs being 0.25 OD and 0.02 OS. Most patients had a relatively slow and stable disease progression. Nystagmus was noticed in all three patients from family OA01. Fundus presentations of all patients demonstrated bilateral optic nerve head pallor (Figure 2). VEP results were attainable in five patients, including OA02-II:2, OA08-I:1, OA08-II:1, OA12-I:1, and OA12-II:1. All patients showed bilateral diminished VEP presentations. None of the patients presented systemic abnormalities.

Genetic investigation: Probands from all 15 families were selected for NGS, as mentioned before. After a comprehensive genetic analysis, 14 heterozygous mutations in total in the OPA1 gene (NM_130837) were identified as potentially disease causing in the 15 families, including eight novel variants and six recurrent mutations (Figure 3 and Table 2). Eleven of the 14 mutations were located in the GTPase domain and dynamin central region (Figure 4A). All identified variants segregated the disease phenotypes in corresponding families and were absent in 150 unrelated normal controls. The eight novel variations comprised three missense mutations (c.193C>G in family OA02, c.968A>G in family OA01, and c.2126A>G in family OA13), one deletion...
(c.1036_1038del in family OA15), two nonsense mutations (c.987_988del in family OA07 and c.1071dupT in family OA05), and two splice site mutations (c.1036–1G>C in family OA12, and c.2012+2T>G in family OA08; Figure 1 and Figure 3, and Table 2). The novel missense variant c.968A>G, leading to the amino acid change from tyrosine to cysteine at residue 323 (p.Y323C), was located within the GTPase domain of the OPA1 protein (NP_570850; Figure 4A). A conservational analysis indicated that residue Tyr323 in OPA1 was evolutionarily conserved among multiple species (Figure 4B). Potential deleterious effects of this mutation was implied by all three types of online predicting software, including PROVEN (~8.03, deleterious), SIFT (0.000, damaging), and Polyphen-2 (1.000, probably damaging; Table 2). Another variant c.193C>G, causing substitution from leucine to valine at conserved residue 65 (p.L65V), was located in the basic domain of the OPA1 protein (Figure 4A,B). This variation was predicted to be damaging (0.016) by the SIFT online predicting software (Table 2). The other missense mutation, c.2126A>G, leading to the transformation from aspartic

Figure 3. Chromatograms of wild-type (top) and mutant (bottom) OPA1 sequences in all recruited families.
Table 2. Characteristics of identified OPA1 mutations.

| Family ID | Mutation | Amino acid | Type | Status | Exon | Bioinformatics Analysis | Reported /Novel | MAF |
|-----------|----------|------------|------|--------|------|-------------------------|-----------------|-----|
| OA01      | c.968A>G  | p.Y323C    | missense | Het    | E10  | DA (0.000) PD (1.000) DE (−8.03) | Novel | -   |
| OA02      | c.193C>G  | p.L65V     | missense | Het    | E2   | DA (0.016) B (0.278) N (−0.63) | Novel | -   |
| OA03      | c.1499G>A | p.R500H    | missense | Het    | E16  | DA (0.001) PD (1.000) DE (−4.70) | CM030379 | -   |
| OA04      | c.1800C>A | p.S600R    | missense | Het    | E19  | DA (0.001) PD (1.000) DE (−4.64) | CM061154 | -   |
| OA05      | c.1071dupT| p.T358*    | nonsense | Het    | E11  | -                       | -               | Novel |-   |
| OA06      | c.1034G>A | p.R345Q    | missense | Het    | E10  | DA (0.041) PD (0.978) DE (−3.50) | CM002636 | -   |
| OA07      | c.987_988del | p.S331*   | nonsense | Het    | E10  | -                       | -               | Novel |-   |
| OA08      | c.2012+2T>G | -         | splice site | Het    | E22–23 | -                      | -               | Novel |-   |
| OA09      | c.2873_2876del | p.V958Gfs*2 | frameshift | Het    | E29  | -                       | -               | [26] 4/121408 |   |
| OA10      | c.1499G>A | p.R500H    | missense | Het    | E16  | DA (0.001) PD (1.000) DE (−4.70) | CM030379 | -   |
| OA11      | c.112C>T  | p.R38*     | nonsense | Het    | E2   | -                       | -               | CM024785 | -   |
| OA12      | c.1036–1G>C | -         | splice site | Het    | E10–11 | -                      | -               | Novel | -   |
| OA13      | c.2126A>G  | p.D709G    | missense | Het    | E22  | DA (0.001) PD (1.000) DE (−6.72) | Novel | -   |
| OA14      | c.804_805del | p.K269Nfs*1 | frameshift | Het    | E8   | -                       | -               | [27] | -   |
| OA15      | c.1036_1038del | p.V346del | deletion | Het    | E11  | -                       | -               | Novel | -   |

Abbreviations: Het: heterozygous; DA: damaging; PD: probably damaging; B: benign; DE: deleterious; N: neutral; MAF: minor allele frequency.

We next used the SROOGLE online prediction software to determine whether the two splice site variations would cause abolishment of the regular splicing sites. According to our data, mutation c.1036–1G>C was found to remarkably decrease the splice site score from 4.81 to −3.26 in the Max entropy model and from 81.06 to 57.62 in the PSSM model. The regular splice site was found completely abolished by mutation c.2012+2T>G. The nonsense mutations c.987_988del and c.1071dupT would introduce immediate translation stop codons at residues 331 and 358, respectively, thus generating a truncated protein or causing nonsense-mediated mRNA decay (NMD).

**DISCUSSION**

Herein, we report the identification of 14 heterozygous OPA1 variants in 15 Chinese OA families, including eight novel and six recurrent mutations. All included patients show typical OA presentation. Some of the literature suggests that gender might contribute to the severity of OA caused by an OPA1 mutation [19]. However, our data do not reveal such a correlation. The average onset age of female patients ranged from infant to 12 years old (average: 6.63 years old), and the average onset age of male patients ranged from 3 to 12 years old (average: 5.93 years old). The OA progression shows no notable difference between males and females. Of all included patients, 15 are male and eight are female. The greater number of male patients in this study is probably due to the de novo OPA1 mutations in families OA07, OA09, OA10, and OA15.

The OPA1 protein plays an important role in maintaining the mitochondrial structure and inhibiting apoptosis. The N-terminal mitochondrial localization signal sequence of OPA1 can direct protein into the mitochondria. Recent studies indicate that OPA1 proteins accumulate in the mitochondrial inner membrane and serve as anchors for mitochondrial DNA (mtDNA), contributing to its replication and distribution [20,21]. OPA1 insufficiency could disrupt oxidative phosphorylation, disturb mtDNA maintenance and replication, and further interrupt regular mitochondrial function [21]. Changes in mitochondrial genome stability would further cause ATP insufficiency, abnormal cellular function, apoptosis, and ADOA phenotype. Two frameshift, two splice-site, and three nonsense mutations are identified in this study, which are predicted to generate truncated OPA1 proteins or lead to NMD. According to previous reports, the nonsense...
Figure 4. Diagrammatic representation and conservational analyses. A: Diagrammatic representation of the 14 identified mutations in the context of genome structure (upper) and eight isoforms of the OPA1 protein (below), derived from the alternative splicing of exons 4, 4b, 5, and 5b. The OPA1 protein includes a mitochondria-targeting sequence (MTS), a GTPase domain, a middle domain, and a C-terminus GTPase effector domain (GED). B: Orthologous protein sequence alignment of OPA1 from human (*H. sapiens*), chimpanzees (*P. troglodytes*), cows (*B. taurus*), rats (*M. musculus*), chickens (*G. gallus*), zebrafish (*D. rerio*), fruit flies (*D. melanogaster*), and roundworms (*C. elegans*).
mutation OPA1 Q285STOP would cause NMD in a murine model. This partial loss of OPA1 causes mitochondrial respiratory deficiency and a substantial resistance to endoplasmic reticulum stress-induced death [22,23]. Another frameshift mutation, OPA1 329_355del, is also found to cause a 50% reduction in the OPA1 protein in a murine model [24]. The OPA1329_355del mice are found to develop visual dysfunction due to RGC loss and an ascending optic neuropathy, while the earliest changes detected in OPA1Q285STOP mice are RGC dendritic changes leading to dysfunctional RGCs. In conclusion, we revealed eight novel and six recurrent mutations identified in this study are more likely to exert a dominant-negative or deleterious gain-of-function effect [25]. More experiments are still warranted to understand better the pathogenesis of OPA1 mutations.

Sometimes, clinical diagnoses are challenging in young patients with non-fully manifested phenotypes or due to the clinical heterogeneity with which hereditary retinal diseases manifest. Therefore, genetic tests should be kept be continuously researched to aid unclear clinical diagnoses and to prognosticate the disease. Genetic diagnosis also promises gene therapy or other forms of gene-specific treatments. In our study, we found eight novel and six recurrent mutations in the OPA1 gene in 15 Chinese OA families. Our findings expand the OPA1 mutational spectrum, enrich their phenotype–genotype correlations, provide crucial hints for genetic consultation in these families, and further help with better clinical management.

APPENDIX 1. PRIMERS USED IN THIS STUDY.

To access the data, click or select the words “Appendix 1.”

ACKNOWLEDGMENTS

We thank all patients and their family members for their valuable contribution to this study. We also thank EENT Biobank for sample collection and management. This work is supported by the National Natural Science Foundation of China (81525006, 81670864 and 81730025 to C.Z., and 81700877 to X.C.); Natural Science Foundation of Jiangsu Province (BK20171087 to X.C.); Shanghai Outstanding Academic Leaders (2017BR013 to C.Z.); Open Foundation of State Key Laboratory of Reproductive Medicine (Nanjing Medical University, SKLRM-KA201607 to X.C.) and a project funded by the Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions. The co-corresponding authors are Min Wang, email: wangmin83@yahoo.com, Chen Zhao, email: dr_zhaochen@i63.com, and Xue Chen, email: drcx1990@vip.i63.com.

REFERENCES

1. Chun BY, Rizzo JF 3rd. Dominant optic atrophy: updates on the pathophysiology and clinical manifestations of the optic atrophy 1 mutation. Curr Opin Ophthalmol 2016; 27:475-80. [PMID: 27585216].

2. Amati-Bonneau P, Milea D, Bonneau D, Chevrier A, Ferre M, Guilhet V, Gueguen N, Loiseau D, de Crescenzo MA, Verny C, Procaccio V, Lenaers G, Reynier P. OPA1-associated disorders: phenotypes and pathophysiology. Int J Biochem Cell Biol 2009; 41:1855-65. [PMID: 19389487].

3. Millet AM, Bertholet AM, Daloyau M, Reynier P, Galinier A, Devin A, Wissinguer B, Belenguer P, Davezac N. Loss of functional OPA1 unbalances redox state: implications in dominant optic atrophy pathogenesis. Ann Clin Transl Neurol 2016; 3:308-21. [PMID: 27547769].

4. Belenguer P, Pellegrini L. The dynamin GTPase OPA1: more than mitochondria? Biochim Biophys Acta 2013; 1833:176-83. [PMID: 22902477].

5. Eiberg H, Kjer B, Kjer P, Rosenberg T. Dominant optic atrophy (OPA1) mapped to chromosome 3q region. 1. Linkage analysis. Hum Mol Genet 1994; 3:977-80. [PMID: 7951248].

6. Frezza C, Cipolat S, Martins de Brito O, Micaroni M, Benznousenko GV, Rudka T, Bartoli D, Polishuck RS, Danial NN, De Strooper B, Scorrano L. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell 2006; 126:177-89. [PMID: 16839885].

7. Zhang L, Shi W, Song L, Zhang X, Cheng L, Wang Y, Ge X, Li W, Zhang W, Min Q, Jin ZB, Qu J, Gu F. A recurrent deletion mutation in OPA1 causes autosomal dominant optic atrophy in a Chinese family. Sci Rep 2014; 4:6936-[PMID: 25374051].

8. Reynier P, Amati-Bonneau P, Verny C, Olichon A, Simard G, Guichet A, Bonnemains C, Malecaze F, Malenge MC, Pelletier JB, Calvas P, Dolfus H, Belenguer P, Malthiery Y, Lenaers G, Bonneau D. OPA3 gene mutations responsible for autosomal dominant optic atrophy and cataract. J Med Genet 2004; 41:e110-[PMID: 15342707].

9. Amati-Bonneau P, Valentino ML, Reynier P, Gallardo ME, Bornstein B, Boissiere A, Campos Y, Rivera H, de la Aleja JG, Carroccia R, Iommarini L, Labauge P, Figarella-Branger D, Marcqelles P, Furby A, Beauvais K, Letournel F, Li, Morga C, Montagna P, Liguori M, Zanna C, Rugolo M, Cossarizza A, Wissinguer B, Verny C, Schwarzenbacher R, Martin MA, Arenas J, Ayuso C, Garese R, Lenaers G, Bonneau D, Carelli V. OPA1 mutations induce mitochondrial DNA instability and optic atrophy ‘plus’ phenotypes. Brain 2008; 131:338-51. [PMID: 18158317].

10. Ahmad KE, Davis RL, Sue CM. A novel OPA1 mutation causing variable age of onset autosomal dominant optic atrophy plus in an Australian family. J Neurol 2015; 262:2323-8. [PMID: 26194196].

11. Gu S, Tian Y, Chen X, Zhao C. Targeted next-generation sequencing extends the phenotypic and mutational spectrums for EYS mutations. Mol Vis 2016; 22:646-57. [PMID: 27375351].
12. Rong W, Chen X, Zhao K, Liu Y, Liu X, Ha S, Liu W, Kang X, Sheng X, Zhao C. Novel and recurrent MYO7A mutations in Usher syndrome type 1 and type 2. PLoS One 2014; 9:e97808. [PMID: 24831256].

13. Chen X, Liu Y, Sheng X, Tam PO, Zhao K, Rong W, Liu X, Pan X, Chen LJ, Zhao Q, Vollrath D, Pang CP, Zhao C. PRPF4 mutations cause autosomal dominant retinitis pigmentosa. Hum Mol Genet 2014; 23:2926-39. [PMID: 24493197].

14. Chen X, Zhao K, Sheng X, Li Y, Gao X, Zhang X, Kang X, Pan X, Liu Y, Jiang C, Shi H, Rong W, Chen LJ, Lai TY, Wang X, Yuan S, Liu Q, Vollrath D, Pang CP, Zhao C. Targeted sequencing of 179 genes associated with hereditary retinal dystrophies and 10 candidate genes identifies novel and known mutations in patients with various retinal diseases. Invest Ophthalmol Vis Sci 2013; 54:2186-97. [PMID: 23462753].

15. Chen X, Sheng X, Liu X, Li H, Liu Y, Rong W, Ha S, Liu W, Kang X, Zhao K, Zhao C. Targeted next-generation sequencing reveals novel USH2A mutations associated with diverse disease phenotypes: implications for clinical and molecular diagnosis. PLoS One 2014; 9:e105439. [PMID: 25133613].

16. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4:1073-81. [PMID: 19561590].

17. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7:248-9. [PMID: 20354512].

18. Choi Y, Chan AP. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. Bioinformatics 2015; 31:2745-7. [PMID: 25851949].

19. Sarzi E, Seveno M, Angebault C, Milea D, Ronnback C, Quiles M, Adrian M, Grenier J, Cailland A, Lacroux A, Laverge C, Reynier P, Larsen M, Hamel CP, Delettre C, Lenaers G, Muller A. Increased steroidogenesis promotes early-onset and severe vision loss in females with OPA1 dominant optic atrophy. Hum Mol Genet 2017; 26:4764- [PMID: 29045675].

20. Del Dotto V, Mishra P, Vidoni S, Fogazza M, Maresca A, Caporal L, McCaffery JM, Cappelletti M, Baruffini E, Lenaers G, Chan D, Rugolo M, Carelli V, Zanna C. OPA1 Isoforms in the Hierarchical Organization of Mitochondrial Functions. Cell Reports 2017; 19:2557-71. [PMID: 28636943].

21. Elachouri G, Vidoni S, Zanna C, Pattyn A, Boukhaddaoui H, Gaget K, Yu-Wai-Man P, Gasparre G, Sarzi E, Delettre C, Olichon A, Loiseau D, Reynier P, Chinnery PF, Rotig A, Carelli V, Hamel CP, Rugolo M, Lenaers G. OPA1 links human mitochondrial genome maintenance to mtDNA replication and distribution. Genome Res 2011; 21:12-20. [PMID: 20974897].

22. Kushnareva Y, Seong Y, Andreyev Y, Kuwana T, Kiess M, Votruba M, Newmeyer DD. Mitochondrial dysfunction in an Opa1(Q285STOP) mouse model of dominant optic atrophy results from Opal haploinsufficiency. Cell Death Dis 2016; 7:e2309. [PMID: 27468866].

23. Williams PA, Morgan JE, Votruba M. Opal deficiency in a mouse model of dominant optic atrophy leads to retinal ganglion cell dendrophytosis. Brain 2010; 133:2942-51. [PMID: 20817698].

24. Williams PA, Morgan JE, Votruba M. Mouse models of dominant optic atrophy: what do they tell us about the pathophysiology of visual loss? Vision Res 2011; 51:229-34. [PMID: 20801145].

25. Yu-Wai-Man P, Sitarz KS, Samuels DC, Griffiths PG, Reeve AK, Bindoff LA, Horvath R, Chinnery PF. OPA1 mutations cause cytochrome c oxidase deficiency due to loss of wild-type mtDNA molecules. Hum Mol Genet 2010; 19:3043-52. [PMID: 20482224].

26. Delettre C, Lenaers G, Griffioen JM, Gigarel N, Lorenzo C, Belenguer P, Pelloquin L, Grosgeorge J, Turc-Carel C, Perret E, Astarie-Dequeker C, Lasquellec L, Arnaud B, Ducommun B, Kaplan J, Hamel CP. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet 2000; 26:207-10. [PMID: 11017079].

27. Yu-Wai-Man P, Griffiths PG, Burke A, Sellar PW, Clarke MP, Gnanaraj L, A-Kine D, Hudson G, Czermin B, Taylor RW, Horvath R, Chinnery PF. The prevalence and natural history of dominant optic atrophy due to OPA1 mutations. Ophthalmology 2010; 117:1538-46. [PMID: 20417570].

Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China. The print version of this article was created on 31 December 2019. This reflects all typographical corrections and errata to the article through that date. Details of any changes may be found in the online version of the article.